Stockscreener 앱 받기
12.36
1.15%
0.14
시간 외 거래:
12.36
전일 마감가:
$12.22
열려 있는:
$12.15
하루 거래량:
72,070
Relative Volume:
0.64
시가총액:
$328.54M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.79%
1개월 성능:
-4.70%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.76
$12.69
1주일 범위
$11.76
$13.37
52주 변동 폭
$11.76
$16.20
Carlsmed Inc Stock (CARL) Company Profile
명칭
Carlsmed Inc
전화
858-295-9290
주소
1800 ASTON AVENUE, CARLSBAD
CARL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
12.36 | 324.82M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
293.49 | 47.98B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
84.49 | 15.41B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
65.82 | 12.54B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
95.03 | 8.17B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.49 | 7.08B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-18 | 개시 | BTIG Research | Buy |
| 2025-08-18 | 개시 | BofA Securities | Buy |
| 2025-08-18 | 개시 | Goldman | Buy |
| 2025-08-18 | 개시 | Piper Sandler | Overweight |
| 2025-08-18 | 개시 | Truist | Buy |
Carlsmed Inc 주식(CARL)의 최신 뉴스
Carlsmed Secures $60 Million Credit Facility Amendment - MSN
Carlsmed, Inc. (CARL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Carlsmed, Inc. (NASDAQ:CARL) Sees Significant Decrease in Short Interest - MarketBeat
Carlsmed, Inc. (CARL) Stock Price, News, Quote & History - Yahoo! Finance Canada
carlsmed, inc. Earnings dates - RTTNews
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | User | thepilotnews.com - FinancialContent
Carlsmed, Inc.Common Stock (Nasdaq:CARL) Stock Quote - FinancialContent
Carlsmed, Inc. (NASDAQ:CARL) Short Interest Update - MarketBeat
ETFs Investing in Carlsmed, Inc. Stocks - TradingView
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - MSN
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
Carlsmed, Inc.(NasdaqGS: CARL) added to Russell 3000E Growth Benchmark - MarketScreener
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed Inc (CARL) 재무 분석
Carlsmed Inc (CARL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.28%
1.24%
자본화:
|
볼륨(24시간):